Cargando…

Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population

BACKGROUND: Long intergenic non-protein coding RNA, a regulator of reprogramming (ROR), has been found to play an oncogene role in various human malignant tumors. This meta-analysis aimed to synthesize available data to verify the association between clinical prognosis value and ROR expression level...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shengquan, Chen, Jian, Yu, Yang, Li, Deli, Huang, Mengyuan, Yuan, Li, Yin, Guoyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197826/
https://www.ncbi.nlm.nih.gov/pubmed/30410399
http://dx.doi.org/10.2147/CMAR.S174143
_version_ 1783364848018522112
author Yang, Shengquan
Chen, Jian
Yu, Yang
Li, Deli
Huang, Mengyuan
Yuan, Li
Yin, Guoyong
author_facet Yang, Shengquan
Chen, Jian
Yu, Yang
Li, Deli
Huang, Mengyuan
Yuan, Li
Yin, Guoyong
author_sort Yang, Shengquan
collection PubMed
description BACKGROUND: Long intergenic non-protein coding RNA, a regulator of reprogramming (ROR), has been found to play an oncogene role in various human malignant tumors. This meta-analysis aimed to synthesize available data to verify the association between clinical prognosis value and ROR expression level. MATERIALS AND METHODS: We performed a systematic search by using PubMed (Medline), Embase, Cochrane Library, ScienceDirect, Springer, and ISI Web of Knowledge from inception to November 15, 2017. Eleven studies with 903 patients were included in this meta-analysis according to the exclusion and inclusion criteria, and the quality of the publications was assessed by using the Newcastle-Ottawa Scale. Pooled odds ratios (OR) and hazard ratios (HR) with 95% CI were used to describe the effect. RESULTS: The results showed that overexpression of ROR is positively associated with lymph node metastasis (OR=4.472, 95% CI: 3.212–6.225, Z=8.87, P=0.000), tumor invasion depth (OR=9.93, 95% CI: 5.33–18.47, Z=7.24, P<0.001), TNM stage (III/IV vs I/II, OR=2.96, 95% CI: 2.18–4.02, Z=6.95, P<0.001), distant metastasis (OR=3.142, 95% CI: 2.187–4.513, Z=6.20, P<0.001) respectively. Additionally, high expression of ROR was significantly correlated with unfavorable disease-free survival (DFS) (HR=2.74, 95% CI: 1.65–3.82, Z=4.93, P=0.000) and overall survival (OS) (HR=2.09, 95% CI: 1.64–2.54, Z=9.07, P<0.001). Subgroup analysis demonstrated that neither cancer type (digestive or respiratory system) nor sample size (more or less than 100) did not alter the prognostic value of ROR. Furthermore, we performed publication bias and sensitivity analysis in order to examine the stability of meta-analysis of ROR along with OS, which showed that the shape of the funnel plot was nearly symmetrical and the resulting pattern was not significantly influenced while disconnecting each suitable study. CONCLUSION: In accordance with these results, we suggested that the overexpression of long noncoding RNA ROR could act as a novel biomarker for predicting poor prognosis in different human cancers.
format Online
Article
Text
id pubmed-6197826
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61978262018-11-08 Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population Yang, Shengquan Chen, Jian Yu, Yang Li, Deli Huang, Mengyuan Yuan, Li Yin, Guoyong Cancer Manag Res Original Research BACKGROUND: Long intergenic non-protein coding RNA, a regulator of reprogramming (ROR), has been found to play an oncogene role in various human malignant tumors. This meta-analysis aimed to synthesize available data to verify the association between clinical prognosis value and ROR expression level. MATERIALS AND METHODS: We performed a systematic search by using PubMed (Medline), Embase, Cochrane Library, ScienceDirect, Springer, and ISI Web of Knowledge from inception to November 15, 2017. Eleven studies with 903 patients were included in this meta-analysis according to the exclusion and inclusion criteria, and the quality of the publications was assessed by using the Newcastle-Ottawa Scale. Pooled odds ratios (OR) and hazard ratios (HR) with 95% CI were used to describe the effect. RESULTS: The results showed that overexpression of ROR is positively associated with lymph node metastasis (OR=4.472, 95% CI: 3.212–6.225, Z=8.87, P=0.000), tumor invasion depth (OR=9.93, 95% CI: 5.33–18.47, Z=7.24, P<0.001), TNM stage (III/IV vs I/II, OR=2.96, 95% CI: 2.18–4.02, Z=6.95, P<0.001), distant metastasis (OR=3.142, 95% CI: 2.187–4.513, Z=6.20, P<0.001) respectively. Additionally, high expression of ROR was significantly correlated with unfavorable disease-free survival (DFS) (HR=2.74, 95% CI: 1.65–3.82, Z=4.93, P=0.000) and overall survival (OS) (HR=2.09, 95% CI: 1.64–2.54, Z=9.07, P<0.001). Subgroup analysis demonstrated that neither cancer type (digestive or respiratory system) nor sample size (more or less than 100) did not alter the prognostic value of ROR. Furthermore, we performed publication bias and sensitivity analysis in order to examine the stability of meta-analysis of ROR along with OS, which showed that the shape of the funnel plot was nearly symmetrical and the resulting pattern was not significantly influenced while disconnecting each suitable study. CONCLUSION: In accordance with these results, we suggested that the overexpression of long noncoding RNA ROR could act as a novel biomarker for predicting poor prognosis in different human cancers. Dove Medical Press 2018-10-15 /pmc/articles/PMC6197826/ /pubmed/30410399 http://dx.doi.org/10.2147/CMAR.S174143 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yang, Shengquan
Chen, Jian
Yu, Yang
Li, Deli
Huang, Mengyuan
Yuan, Li
Yin, Guoyong
Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population
title Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population
title_full Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population
title_fullStr Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population
title_full_unstemmed Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population
title_short Long noncoding RNA ROR as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the Asian population
title_sort long noncoding rna ror as a novel biomarker for progress and prognosis outcome in human cancer: a meta-analysis in the asian population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197826/
https://www.ncbi.nlm.nih.gov/pubmed/30410399
http://dx.doi.org/10.2147/CMAR.S174143
work_keys_str_mv AT yangshengquan longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation
AT chenjian longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation
AT yuyang longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation
AT lideli longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation
AT huangmengyuan longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation
AT yuanli longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation
AT yinguoyong longnoncodingrnarorasanovelbiomarkerforprogressandprognosisoutcomeinhumancancerametaanalysisintheasianpopulation